Prescription errors in older individuals with an intellectual disability: Prevalence and risk factors in the Healthy Ageing and Intellectual Disability Study
Highlights
► Drug prescribing to older individuals with an intellectual disability (ID) is complex. ► The prevalence of individuals with prescription errors in this population is 47.5%. ► Relevant errors were identified in 26.8% of the individuals. ► Age, level of ID, Body Mass Index and frailty index are potential risk factors for errors. ► Polypharmacy and drugs for the nervous system are also associated with errors.
Introduction
Inappropriate prescribing of pharmacotherapy occurs in about 20–40% of older individuals in the general population (Stafford et al., 2011, van der Hooft et al., 2005, Zaveri et al., 2010). Polypharmacy, i.e. concomitant use of five or more drugs, is also very common among these older people (Heuberger and Caudell, 2011, Stafford et al., 2011) and has been identified as a risk factor for the occurrence of prescription errors (Stafford et al., 2011).
The life expectancy of older individuals with an intellectual disability (ID) is increasing and age-related frailty seems to start at a younger age (Evenhuis, Hermans, Hilgenkamp, Bastiaanse, & Echteld, 2012). As a result, polypharmacy is very common among individuals with an intellectual disability aged 50 years and older. For example, antipsychotics, that have been associated with inappropriate prescriptions in older individuals in general (Stafford et al., 2011), are frequently used by individuals with an ID to treat psychiatric diseases and behavioural problems (de Kuijper et al., 2010). Additionally, chronic somatic diseases, such as epilepsy (Beavis, Kerr, & Marson, 2007) and gastro-esophageal reflux disease (Bohmer, Klinkenberg-Knol, Niezen-de Boer, & Meuwissen, 2000), frequently require pharmacotherapy. Other factors that may increase the complexity of prescribing drugs to older individuals with an ID are the often atypical symptoms of disease (Stolker, Koedoot, Heerdink, Leufkens, & Nolen, 2002); the impaired ability to communicate about disease and effectiveness of pharmacotherapy (Stolker et al., 2002); and the limited evidence for treatment of mental and behavioural problems with psychotropic drugs (Ulzen & Powers, 2008).
As a result, older individuals with an ID may be especially at risk of prescription errors. However, the prevalence of prescription errors and risk factors for such errors have not been established in this population. Therefore, the objectives of this study were (1) to determine the prevalence of older individuals with an intellectual disability with at least one prescription error and (2) to identify potential risk factors for these prescription errors.
Section snippets
Design
A cross-sectional study was performed to determine the prevalence of older individuals with an intellectual disability with at least one prescription error and to identify potential risk factors for these errors.
Setting and study population
The included research population in this study consisted of older individuals with an ID using one or more medicines who participated in the study titled “Healthy Ageing and Intellectual Disability” (HA-ID) (Hilgenkamp et al., 2011).
The cohort from the Erasmus MC HA-ID study (Hilgenkamp
Study population
Of the 1050 individuals with an ID included in the HA-ID study, 820 persons used one or more medicines at the time of inclusion of which 600 were randomly selected. In total 2773 prescriptions of these randomly selected individuals were screened for errors. Characteristics of the selected individuals and differences between this sample and the HA-ID cohort are presented in Table 2. Individuals in centralized settings were slightly overrepresented in our sample. Probably, individuals living in a
Discussion
This study, performed in a representative population, shows that prescription errors are frequently identified in older individuals with an intellectual disability. The prevalence of individuals with prescription errors in our population was 47.5% and relevant errors were identified in 26.8% of included individuals. Higher age, less severe intellectual disability, polypharmacy and use of drugs acting on the central nervous system showed a significant association with both all prescription
Conflict of interest
Authors declare that there are no conflicts of interest.
References (19)
- et al.
Gastroesophageal reflux disease in intellectually disabled individuals: How often, how serious, how manageable?
The American Journal of Gastroenterology
(2000) - et al.
Study healthy ageing and intellectual disabilities: Recruitment and design
Research in Developmental Disabilities
(2011) - et al.
Pharmacological interventions for epilepsy in people with intellectual disabilities
Cochrane Database of Systematic Reviews
(2007) - CBO. Dutch Institute for Healthcare Improvement. Guidelines. http://www.cbo.nl/en/Guidelines Accessed...
- et al.
Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: Prevalence and reasons for prescription
Journal of Intellectual Disability Research
(2010) - et al.
Frailty and disability in older adults with intellectual disabilities: Results from the healthy ageing and intellectual disability study
Journal of the American Geriatrics Society
(2012) - et al.
Polypharmacy and nutritional status in older adults: A cross-sectional study
Drugs and Aging
(2011) - NHG, Nederlands Huisartsen Genootschap (Dutch college of general practitioners). Richtlijnen....
- NvAvG, Nederlandse Vereniging van Artsen voor Verstandelijk Gehandicapten (Netherlands’ Society of Physicians for...